Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration Market Report 2025

The endoscopic ultrasound (EUS)-guided fine needle aspiration market size has grown strongly in recent years. It will grow from $0.64 billion in 2024 to $0.7 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to the rising prevalence of gastrointestinal cancers, increasing demand for minimally invasive diagnostic procedures, growing awareness of early cancer detection, expanding adoption in academic and research institutions, and a growing elderly population with chronic diseases.

The endoscopic ultrasound (EUS)-guided fine needle aspiration market size is expected to see strong growth in the next few years. It will grow to $0.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to the increasing need for real-time imaging during procedures, rising preference for outpatient diagnostic services, growing focus on precision medicine, expanding applications in pancreatic lesion diagnosis, and increasing demand for rapid and accurate biopsy techniques. Key trends in this period include technological advancements in ultrasound imaging systems, innovations in needle design and functionality, development of real-time cytological evaluation tools, investment in robotic-assisted endoscopy, and the emergence of artificial intelligence-assisted diagnostic platforms.

The increasing incidence of pancreatic disorders is expected to drive the growth of the endoscopic ultrasound (EUS)-guided fine needle aspiration market in the coming years. Pancreatic disorders encompass diseases and conditions affecting the pancreas, including inflammation, tumors, and functional impairments that influence digestion and hormone production. The rise in these disorders is linked to the growing prevalence of diabetes, which places additional stress on the pancreas and contributes to both inflammatory and functional pancreatic conditions. Endoscopic ultrasound (EUS)-guided fine needle aspiration plays a key role in managing pancreatic disorders by providing minimally invasive, accurate sampling of pancreatic lesions, aiding the diagnosis of conditions such as cancer, cysts, and chronic pancreatitis. For example, in February 2025, Cancer Australia, an Australian government agency, reported that pancreatic cancer caused 3,687 deaths in Australia in 2022 (1,912 males and 1,775 females), increasing to 3,902 deaths in 2024 (2,027 males and 1,875 females). Therefore, the rising prevalence of pancreatic disorders is propelling the growth of the EUS-guided fine needle aspiration market.

Key players in the EUS-guided fine needle aspiration market are focusing on innovations in needle technology, such as endoscopic ultrasound fine biopsy needles, to improve precision and tissue yield during procedures. Endoscopic ultrasound fine biopsy needles are specialized devices designed to obtain core tissue samples during EUS-guided procedures, enabling more accurate histological diagnoses compared to conventional aspiration needles. For instance, in May 2024, Cook Medical, a US-based medical device company, launched the EchoTip ClearCore EUS Biopsy Needle, a next-generation device for precision biopsies of gastrointestinal lesions. This 22-gauge needle is compatible with an ultrasound endoscope for fine needle biopsies (FNB) of submucosal and extramural lesions, mediastinal masses, lymph nodes, and intraperitoneal masses near or within the gastrointestinal tract. It features a cobalt-chromium Franseen tip for enhanced sharpness, allowing tissue puncture with minimal force and precise control, along with a flexible, spring-coiled sheath for access to challenging anatomical locations.

In January 2024, Canon Medical Systems Corporation, a Japan-based medical equipment company, partnered with Olympus Corporation to develop and commercialize advanced endoscopic ultrasound systems. This collaboration aims to provide high-quality diagnostic imaging, improving diagnostic performance and supporting early detection and minimally invasive treatment of diseases, initially targeting markets in Japan and Europe with plans for global expansion. Olympus Corporation, also based in Japan, manufactures optics and reprography products and offers a range of devices for EUS-guided fine needle aspiration (FNA).

Major players in the endoscopic ultrasound (EUS)-guided fine needle aspiration market are Medtronic plc, Fujifilm Holdings Corporation, Becton Dickinson and Company, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Steris plc, Cook Medical LLC, Canon Medical Systems Corporation, CONMED Corporation, Pentax Medical, Argon Medical Devices Inc., Fannin Limited, Zhejiang Soudon Medical Technology Co. Ltd., Micro-Tech Endoscopy USA Inc., CIVCO Medical Solutions, Medorah Meditek Pvt. Ltd., ACE Medical Devices Pvt. Ltd., ENDO-FLEX GmbH, Limaca Medical Ltd., Medi-Globe GmbH, and ZKSK Medical Technology Co. Ltd.

North America was the largest region in the endoscopic ultrasound (EUS)-guided fine needle aspiration market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endoscopic ultrasound (EUS)-guided fine needle aspiration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endoscopic ultrasound (EUS)-guided fine needle aspiration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is a minimally invasive diagnostic technique that combines endoscopic ultrasound (EUS) imaging with fine needle aspiration (FNA) to obtain tissue or fluid samples from internal organs or structures. By inserting a thin needle through an ultrasound-equipped endoscope, physicians can access deep internal organs such as the pancreas, lymph nodes, or liver, enabling accurate diagnosis of cancers, cysts, or other abnormalities with minimal invasiveness.

The primary types of EUS-guided fine needle aspiration include enteral endoscopic ultrasound needles and bronchial endoscopic ultrasound needles. Enteral EUS needles are designed for use via the gastrointestinal tract to access and sample organs or structures near the esophagus, stomach, or intestines. Product offerings include manual EUS-FNA needles, powered EUS-FNA needles, procedural accessories, and sample collection devices. These are used for procedures such as tumor diagnosis, cystic lesion evaluation, lymph node biopsies, and solid organ biopsies. EUS-FNA is applied across gastroenterology, oncology, pulmonology, and endocrinology, serving end users such as hospitals, ambulatory surgical centers, specialty clinics, and others.

The endoscopic ultrasound (EUS)-guided fine needle aspiration market research report is one of a series of new reports that provides endoscopic ultrasound (EUS)-guided fine needle aspiration market statistics, including endoscopic ultrasound (EUS)-guided fine needle aspiration industry global market size, regional shares, competitors with an endoscopic ultrasound (EUS)-guided fine needle aspiration market share, detailed endoscopic ultrasound (EUS)-guided fine needle aspiration market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopic ultrasound (EUS)-guided fine needle aspiration industry. This endoscopic ultrasound (EUS)-guided fine needle aspiration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) market consists of sales of echogenic tip needles, real-time imaging probes, stylet systems, sheath stabilizers, and integrated ultrasound biopsy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.